| scholarly article | Q13442814 |
| P50 | author | Sameer Jauhar | Q57013497 |
| Philip McGuire | Q37834611 | ||
| Federico Turkheimer | Q41330642 | ||
| Mattia Veronese | Q42321542 | ||
| Matthew M. Nour | Q42324775 | ||
| James Stone | Q43280374 | ||
| P2093 | author name string | Alice Egerton | |
| Oliver D Howes | |||
| Shitij Kapur | |||
| Sridhar Natesan | |||
| Maria Rogdaki | |||
| Pamela Hathway | |||
| P2860 | cites work | The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 |
| Increased baseline occupancy of D2 receptors by dopamine in schizophrenia | Q24676113 | ||
| Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations | Q28236042 | ||
| Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis | Q28266069 | ||
| Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis | Q28293647 | ||
| The positive and negative syndrome scale (PANSS) for schizophrenia | Q28301751 | ||
| Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA | Q28484113 | ||
| The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 | Q29547745 | ||
| Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans. | Q33707670 | ||
| Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies | Q33833648 | ||
| The clinical global impressions scale: applying a research tool in clinical practice | Q33894649 | ||
| The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function | Q33897463 | ||
| Schizophrenia: an integrated sociodevelopmental-cognitive model | Q34023115 | ||
| Striatal dopamine release in schizophrenia comorbid with substance dependence | Q34028727 | ||
| Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review | Q34034400 | ||
| Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group | Q34167452 | ||
| Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia | Q34507860 | ||
| Dopamine in schizophrenia: a review and reconceptualization | Q34568816 | ||
| "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time | Q34577698 | ||
| The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs | Q34706538 | ||
| Elevated striatal dopamine function linked to prodromal signs of schizophrenia | Q46174418 | ||
| Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects | Q46762114 | ||
| Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe | Q47744319 | ||
| Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations. | Q48108804 | ||
| Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine | Q48220082 | ||
| Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study | Q48245146 | ||
| Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans | Q48259726 | ||
| Dopamine synthesis capacity in patients with treatment-resistant schizophrenia | Q48350915 | ||
| 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods | Q48366038 | ||
| A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). | Q48682640 | ||
| A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia | Q50096180 | ||
| Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. | Q51823957 | ||
| A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). | Q52016777 | ||
| Multiresolution analysis of emission tomography images in the wavelet domain. | Q52136759 | ||
| Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. | Q52573337 | ||
| What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? | Q55023835 | ||
| Clinical predictors of therapeutic response to antipsychotics in schizophrenia | Q35109168 | ||
| Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia | Q35197029 | ||
| Review of the operational definition for first-episode psychosis | Q35673156 | ||
| Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler | Q36433744 | ||
| Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment. | Q36838322 | ||
| Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. | Q36871782 | ||
| Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. | Q36914354 | ||
| The nature of dopamine dysfunction in schizophrenia and what this means for treatment | Q37062793 | ||
| Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study | Q37256211 | ||
| Dose equivalents for second-generation antipsychotics: the minimum effective dose method | Q37598284 | ||
| PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches | Q37606115 | ||
| A systematic review and meta-analysis of the effects of antipsychotic medications on regional cerebral blood flow (rCBF) in schizophrenia: association with response to treatment | Q38201197 | ||
| Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. | Q38948958 | ||
| Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology | Q39029626 | ||
| Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase. | Q39115415 | ||
| Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity | Q39223366 | ||
| The dopamine hypothesis of schizophrenia: a review | Q40550257 | ||
| Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs | Q41326381 | ||
| A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists | Q41594163 | ||
| Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia | Q42190092 | ||
| Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? | Q43253191 | ||
| A reversible tracer analysis approach to the study of effective dopamine turnover | Q43589269 | ||
| PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium | Q43977655 | ||
| Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo | Q44374816 | ||
| Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study | Q44752395 | ||
| A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone | Q44879542 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biological psychiatry | Q2706176 |
| psychosis | Q170082 | ||
| dopamine | Q170304 | ||
| positron emission tomography | Q208376 | ||
| P304 | page(s) | 79-87 | |
| P577 | publication date | 2018-07-11 | |
| P1433 | published in | Biological Psychiatry | Q4914961 |
| P1476 | title | The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study | |
| P478 | volume | 85 |
| Q91595946 | A neuroimaging biomarker for striatal dysfunction in schizophrenia |
| Q99604509 | A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach |
| Q92476399 | Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based-Nomenclature |
| Q90116242 | Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia |
| Q99418608 | Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis |
| Q92480512 | The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research |
| Q91130303 | The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study |
| Q96952371 | The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disorders |
| Q92443894 | Understanding and Predicting Variability in Response to Treatment in Psychotic Disorders: In Vivo Findings |
Search more.